Abraham Havron
Independent DirectorDr. Abraham Havron, also known as Avri, Ph.D. serves as the Chief Executive Officer of Modigene, Inc. Dr. Havron has been the Chief Executive Officer at Modigene Delaware and PROLOR Biotech, Inc. (formerly, ModigeneTech) since 2005. He was Director of PROLOR Biotech Inc. He has biopharmaceutical and biotechnology consultant experience. He founded Interpharm Laboratories Ltd., a subsidiary of Serono and also served as a Director of Research and Development from 1980 to 1987. He served as a Vice President of Manufacturing and Process-Development at Savient Pharmaceuticals, Inc., (formerly BioTechnology General Ltd.) and its subsidiary, Rehovot, Israel from 1987 to 1999. Dr. Havron served as the Chief Technology Officer of Clal Biotechnology Industries Ltd., from 1999 to 2003 and was its Vice President. During his managerial career Dr. Havron was directly involved in the multi-disciplinary development of many biopharmaceuticals seven of which were approved and are marketed worldwide: Rebif (recombinant beta interferon), Biotropin (recombinant human growth hormone), Bio-Hep-B (3rd generation recombinant hepatitis B vaccine), Biolon and Euflexxa (ophthalmic and orthopedic devices containing bacteria derived hyaluronic acid), bio-similar recombinant Insulin and, Nexxobrid (debridement agent for severe burns), Somatrogan- recombinant long acting human growth hormone analog. Dr. Havron has been actively involved in establishing several biotech start-up companies among them Mediwound, Curetech, Prolor-Biotech, Polyheal, PamBio and Enlivex. He served as the Chairman of Polyheal Ltd. He served as the Chairman of Mediwound from 2001 to 2003 and MediWound Ltd. He serves as a Member of the Advisory Board of MedidaMETRICS, Inc. Dr. Havron served as Independent Director of Kamada Ltd. since 2010 until 2018. Dr. Havron is also a board member of CollPlant Ltd. Dr. Havron has been a Director of Modigene Delaware and OPKO Biologics since May 2007 and Modigene, Inc., since May 2007. He serves as Director of Active PX Ltd. He serves as independent at CollPlant Biotechnologies Ltd. (formerly known as CollPlant Holdings Ltd.) since May 2016. He serves as a Director of Modiwound Ltd., Braintact Ltd. and Angio-B Ltd. Dr. Havron serves as Member of Scientific Advisory Board at Allosterix Ltd. He serves as a Member of Advisory Board at ExactCost, Inc. He has been an Independent Director of Enlivex Therapeutics Ltd. since 2014. He served as an External Director of MediWound Ltd. from June 2014 to June 22, 2017. He served as a Research-Fellow at Harvard Medical School in Boston until 1980. He holds Ph.D. Degree in Bio-Organic Chemistry from the Weizmann Institute of Science in 1978, completed his post- doctorate at Harvard Medical School.
Positions
- Company NameEnlivex Ltd.Stock CodeENLVPositionIndependent DirectorColleagues
- SNShai NovikExecutive Chairman
- OHOren HershkovitzChief Executive Officer
- DMDror MevorachFounder & Scientific Advisor
- SSShachar ShlosbergerChief Financial Officer
- VAVeronique Amor-BaroukhChief Operating Officer
- RJRoger James PomerantzIndependent Vice Chairman of the Board
- AHAbraham HavronIndependent Director
- GHGili HartIndependent Director
- MMMitchell M. LevyClinical Advisor
- Company NameCollPlant Biotechnologies Ltd.Stock CodeOPHIPositionIndependent DirectorColleagues
- EREran RotemCEO & CFO
- EPElan PennIndependent Director
- OFOren FahimipoorVice President of Operations
- OSOded ShoseyovFounder & Chief Scientist
- BABar AbelisVice President of Legal
- HDHadas Dreiher HorowitzVice President of Human Resources
- YTYehiel TalDirector
- OLOfer LevyMember of the Scientific Advisory Board & Member of the Clinical Advisory Board
- SSShay SokerMember of Advisory Board
